Goserelin for Breast Cancer: 31 Real Stories

31 stories match breast cancer and goserelin. 26 of them mention surgery.

Cancer Stories

Pilar, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HER2-Positive Breast Cancer: Pilar's Patient Story

Patient Info: Pilar, Female, 40s | Stage IV

Biomarkers: Hormone receptor-positive; HER2-positive

Pilar was living with metastatic hormone receptor-positive, HER2-positive breast cancer, continuing systemic treatment with Zoladex, aromatase inhibitors, trastuzumab, and pertuzumab, and managing side effects with rehabilitation support.

MatchTrial Historias Reales
OutcomeLiving With Cancer
Ana, who was diagnosed with Breast CancerBreast Cancer

Breast Cancer: Ana's Patient Story

Patient Info: Ana, Female, 40s

Biomarkers: Hormone-dependent tumor

Ana completed surgery, 6 months of chemotherapy, and 16 radiation sessions for hormone-dependent breast cancer and continued Tamoxifen plus quarterly Zoladex as recurrence-prevention therapy.

MatchTrial Historias Reales
OutcomeCare Ongoing
Rach, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II HR-Positive Breast Cancer: Rach's Patient Story

Patient Info: Rach D., Female, Under 40 | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of June 2026, Rach described Stage II triple-positive breast cancer treated with fertility preservation, 6 rounds of neoadjuvant TCHP including Herceptin, Zoladex ovarian suppression, and double mastectomy with reconstruction.

The Patient Story
OutcomeCare Ongoing
Tina, who was diagnosed with Stage III Invasive Lobular CarcinomaBreast Cancer

Stage III HR-Positive Invasive Lobular Carcinoma: Tina's Patient Story

Patient Info: Tina, Female, Under 40 | Stage III

Biomarkers: ER-positive

As of June 2026, Tina was in survivorship after double mastectomy, AC-T chemotherapy, radiation, and ongoing hormone therapy with daily tamoxifen and Zoladex every 3 months.

The Patient Story
OutcomeCare Ongoing
Marina, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II Breast Cancer: Marina's Survivor Story

Patient Info: Marina, Female | Stage II

Stage II breast cancer survivor after chemotherapy, with ongoing survivorship advice focused on hair loss, neuropathy, fertility preservation, nausea, fatigue, chemo brain, and support.

The Patient Story
OutcomeSurvivorship / Completed Treatment
Marina, who was diagnosed with Breast CancerBreast Cancer

Triple-Negative Breast Cancer: Marina's Survivor Story

Patient Info: Marina, Female, Under 40

Biomarkers: BRCA1 mutation; triple-negative breast cancer

Triple-negative breast cancer survivor with a BRCA1 mutation who completed treatment after an initial diagnosis and a second diagnosis at the 5-year mark; no formal stage or metastatic disease was stated in the available source text.

The Patient Story
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Stage IIB breast cancer with severe radiation recall after abemaciclib

Patient Info: Anonymized, Female, 40s

Biomarkers: ER-positive; PR-positive; HER2 1+ / HER2-negative

The flap healed after abemaciclib was stopped and the tissue expander/patch were removed, but her long-term cancer-control and reconstruction outcomes were not yet reported.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Breast CancerBreast Cancer

Hormone receptor-positive breast cancer treated with pembrolizumab trial complicated by acquired lipodystrophy

Patient Info: Anonymized, Female, 40s

Biomarkers: HER2-negative breast cancer. Metabolic changes occurred during/after pembrolizumab.

As of December 2025, breast cancer treatment had included neoadjuvant chemotherapy/pembrolizumab, surgery, adjuvant pembrolizumab, and endocrine therapy; CT did not show recurrence during weight-loss evaluation, but she required ongoing metabolic care for pembrolizumab-associated acquired generalized lipodystrophy.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage III Invasive Ductal CarcinomaBreast Cancer

Recurrent breast cancer complicated by T-DXd-associated dermatomyositis and interstitial lung disease

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: Initial tumor had weak ER/AR, PR-negative, HER2 0. Recurrence became ER/PR/AR-negative, HER2-low, PD-L1 CPS ~30.

The cancer progressed after adjuvant therapy and again after 6 cycles of gemcitabine/carboplatin. Trastuzumab deruxtecan was followed by dermatomyositis features and interstitial pneumonia, with symptoms worsening despite glucocorticoid treatment after continued exposure.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

ER/PR/HER2-positive breast cancer: gallbladder, liver, lung, pleural, and bone metastases after incomplete adjuvant therapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Triple-positive breast cancer. Gallbladder metastasis kept ER/PR/HER2 positivity and Ki-67 >40%; markers supported breast origin.

Metastatic Site: gallbladder, liver, lung/pleura, bone

The patient died 3 years and 10 months after lumpectomy after metastatic ER/PR/HER2-positive breast cancer involved the gallbladder, liver, lungs/pleura, and bones following incomplete adjuvant therapy and loss to surveillance.

PubMed Central
OutcomeIn Memory
LaShae, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II HR-Positive Invasive Ductal Carcinoma: LaShae's Patient Story

Patient Info: LaShae, Female, Under 40 | Stage II

Biomarkers: ER-positive; comprehensive genetic panel negative

As of May 2025, LaShae had completed mastectomy for Stage IIB ER-positive breast cancer with 2 positive lymph nodes and was undergoing chemotherapy, with radiation and 5-10 years of hormone therapy planned.

The Patient Story
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV luminal A breast cancer: liver resection and disease-free follow-up

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: luminal A; ER-positive; PgR-positive; HER2-negative

Metastatic Site: lung, liver

Disease-free after R0 hepatic segmentectomy for breast cancer liver metastasis, with May 2021 MRI showing no remaining liver nodules while she continued maintenance letrozole and goserelin.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Breast Cancer Recurrence in the Small Intestine and Bone More Than 5 Years After Diagnosis

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial ER-positive, PR-positive, HER2-negative; metastatic lesion ER-negative, PR-negative, triple negative

Metastatic Site: small intestine, bone, right fallopian tube

More than 5 years after her December 2018 diagnosis, she was alive at 1-year follow-up after metastatic recurrence, with multiple bone metastases still present.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage 4 breast cancer: complete remission with letrozole and palbociclib

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Breast cancer was ER/PR positive, HER2 0

Metastatic Site: pleura/pleural effusion

Breast cancer remained in remission on letrozole after palbociclib was stopped; Ph-positive B-ALL achieved complete response with no molecular residual disease after blinatumomab plus ponatinib, with ongoing monthly outpatient monitoring.

PubMed Central
OutcomeCancer-Free / NED
Jessica, who was diagnosed with Stage I Invasive Lobular CarcinomaBreast Cancer

Stage I Invasive Lobular Carcinoma: Jessica's Patient Story

Patient Info: Jessica, Female, 40s | Stage I

Biomarkers: Myriad genetic testing negative; Oncotype DX score 19; RSClin recurrence risk 19%; isolated tumor cells around 1 sentinel lymph node without invasion

As of July 2024, Jessica had completed bilateral mastectomy for Stage IB ILC and was moving forward with radiation and long-term hormone suppression after chemotherapy was not recommended.

Lobular Breast Cancer Alliance
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Triple-positive breast cancer: complete response to targeted therapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Triple-positive breast cancer; SBDS variants present; no detected TP53 variant on MyeloSeq.

Metastatic Site: liver

Stage IV triple-positive breast cancer with liver metastasis achieved complete response after paclitaxel, trastuzumab, pertuzumab, and G-CSF support; complete response was maintained for 18 months after treatment initiation while on maintenance HER2-directed and endocrine therapy.

PubMed Central
OutcomeCancer-Free / NED
LaShae, who was diagnosed with Breast CancerBreast Cancer

HR-Positive Breast Cancer: LaShae's Patient Story

Patient Info: LaShae, Female, Under 40

Biomarkers: ER-positive; MammaPrint high-risk recurrence; 70-gene hereditary cancer panel negative

As of June 2024, LaShae had completed mastectomy and was undergoing TC chemotherapy, with radiation and long-term hormonal therapy planned; no remission or NED status was stated.

The Patient Story
OutcomeCare Ongoing
Kim, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Invasive Lobular Carcinoma: Kim's Survivor Story

Patient Info: Kim, Female

Biomarkers: ER 99% positive; PR 85% positive; HER2-negative

Kim’s ER-positive, PR-positive, HER2-negative ILC responded strongly to Zoladex and Letrozole before skin-sparing mastectomy, with 90% tumor necrosis, clear margins, no lymph node spread, and confirmation that she was cancer-free.

Lobular Breast Cancer Alliance
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Stage 4 lobular breast cancer: bone therapy switch to denosumab

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Not reported for breast cancer; CRP 21 mg/dL and ESR 27 mm/hr were elevated during orbital inflammation workup

Metastatic Site: bone

As of April 2024, zoledronate-associated ocular inflammation resolved within 2.5 weeks, vision returned to 20/20 after about 3 weeks, and bone-support treatment was changed to denosumab; breast-cancer response was not reported.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Metastatic breast cancer: three years in remission with T-DM1 (Kadcyla) treatment

Patient Info: Anonymized, Female | Stage IV

Biomarkers: HER2-positive; hormone receptor-positive

Metastatic Site: liver; spine / bone

T-DM1 produced a complete clinical and radiological response after 7 cycles, sustained for 41 months and 60 cycles while treatment continued.

PubMed Central
OutcomeComplete Response
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Breast cancer that spread to the thymus gland

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Oestrogen receptor-positive; progesterone receptor-positive; HER2-negative

Metastatic Site: thymus

She had a good response after 4 cycles of abemaciclib, anastrozole and goserelin and continued endocrine treatment with surveillance of the opposite breast.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Breast CancerBreast Cancer

Rare breast blood-vessel cancer (angiosarcoma) in a teenage girl

Patient Info: Anonymized, Female

Biomarkers: Testing for Li-Fraumeni syndrome and POT1 mutation was inconclusive; no inherited cancer predisposition was established

She remained in remission 3 years after diagnosis and continued annual MRI surveillance of the reconstructed and opposite breasts.

PubMed Central
OutcomeCancer-Free / NED